ASP Isotopes to acquire 51% of PET Labs for $2M; plans two new cyclotrons with GE Healthcare

ASP Isotopes Inc.

Acquired 51% of PET Labs for $2M; option to buy remaining 49% for $2.2M by Jan 2027.
Strategic relationship to produce and distribute medical isotopes in frontier markets using cyclotrons.
Plans to add two GE Healthcare cyclotrons in Pretoria and Cape Town, financed by third-party debt.
PET Labs currently operates one cyclotron in Pretoria, expanding radioisotope production.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

ASP Isotopes Inc. entered into Share Purchase Agreement with Nucleonics Imaging Proprietary Limited valued at USD 2,000,000 for 51% of PET Labs shares, with option for remaining 49% for USD 2,200,000 (effective 2023-10-30).

Action: entry
Agreement: asset purchase
Counterparty: Nucleonics Imaging Proprietary Limited
Value: USD 2,000,000 for 51% of PET Labs shares, with option for remaining 49% for USD 2,200,000
Effective: 2023-10-30

Exact text from the filing

On October 30, 2023, ASP Isotopes Inc. (the “Company”) entered into a Share Purchase Agreement (the “Purchase Agreement”) with Nucleonics Imaging Proprietary Limited, a company incorporated in the Republic of South Africa (“Seller”), relating to the purchase and sale of ordinary shares in the issued share capital of Pet Labs Pharmaceuticals Proprietary Limited, a company incorporated in the Republic of South Africa (“PET Labs”).

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

ASP Isotopes Inc. filing history →

Source: SEC EDGAR

accession 0001477932-23-008082

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.